Welcome to the first article in our new series focusing on biotech hotspots both big and small throughout the world, particularly Europe, North America and the APAC regions. This time around, we’re focusing on the Nordics, a distinct region that has been quietly building one of the world’s most sophisticated biotech ecosystems. Sweden, Denmark, Finland, Norway and Iceland represent a unique blend of established pharma heritage and emerging specialized innovation. In this article, you’ll find an overview of key biotech hotspots across these countries.
Sweden
Sweden’s biotech strength is closely tied to its academic and clinical research infrastructure, particularly around institutions such as Karolinska Institutet and the Stockholm-Uppsala cluster. This environment has spawned companies such as BioArctic, which develops treatments for neurodegenerative diseases and has attracted global attention through collaborations with the likes of Novartis and Bristol Myers Squibb.
Calliditas Therapeutics has also demonstrated the strength of Swedish biotech with the development of treatments for rare kidney diseases, while Sobi remains a major international player in rare diseases and specialty care. Sweden also benefits from the presence of AstraZeneca’s major R&D center in Gothenburg, which continues to anchor the country’s life sciences ecosystem.
The Swedish government promotes sector growth through its national Life Science Strategy, which focuses on strengthening clinical research and data-driven healthcare. A prime example of this is the recent launch of WARA Medicine, a research initiative combining AI and medicine, led by AstraZeneca to accelerate drug discovery.
Denmark
Denmark, particularly through the Medicon Valley cluster spanning Copenhagen and southern Sweden, particularly the Skåne region, represents the Nordic’s most concentrated life science ecosystem, being home to approximately 350 biotech and pharmaceutical companies.
Denmark’s industrial strength has been shaped in part by Novo Nordisk, one of Europe’s most valuable companies, whose dominance in diabetes and obesity therapeutics has created a dense ecosystem of suppliers, service providers and spinouts. Genmab, another Danish success story, has become a global leader in antibody therapeutics through blockbuster partnerships with the likes of AbbVie, GSK and Johnson & Johnson.
Finland
Finland has taken a deliberate, government-supported approach to building its biotech sector from the ground up. The country’s strategy centers on structured incubation and commercialization support for research-originated innovations.
Health Incubator Helsinki, established jointly by the City of Helsinki and the University of Helsinki in 2020, exemplifies this approach. The program provides up to three years of customized mentoring, workspace in the Meilahti hospital area and access to a network exceeding 150 organizations. Since 2020, participating startups have raised more than €65 million, with 2025 marking a record year of funding.
Finland’s approach displays a broader Nordic strength: the ability to coordinate public, academic and private resources around shared objectives. The country’s national health-data strategy further positions it for precision medicine applications, leveraging comprehensive population registries larger nations typically don’t possess. Orion Corporation, Finland’s flagship pharmaceutical company, continues to invest in domestic R&D while partnering with smaller biotechs, providing an anchor for the broader ecosystem.
Norway
Norway’s biotech sector is smaller than its Nordic neighbors but distinguished by its ability to leverage unique national assets. The country’s long coastline and Arctic territories provide access to marine biodiversity that few other ecosystems can replicate.
KinSea Lead Discovery, based in Tromsø, is an example of this specialization. The company focuses on identifying and developing marine bioactive compounds from the Arctic Ocean, with oncology-focused lead programs aimed at overcoming limitations of existing therapies.
This marine biotech focus represents a deliberate strategy. Rather than attempting to compete with Sweden’s scale or Denmark’s industrial density, Norway is building differentiated capabilities around its natural advantages. The model serves as an example for smaller ecosystems seeking global relevance without head-on competition with established powers.
Iceland
Iceland’s contribution to Nordic biotech is disproportionately large relative to its population, driven by unique natural and data resources that enable capabilities difficult to replicate elsewhere. The country has developed a particular specialization in human genetics, supported by its relatively homogenous population and comprehensive genealogical and health records.
This approach has been pioneered by deCODE Genetics, which has played a central role in advancing population-scale genomics and linking genetic variation to disease. Iceland’s regulatory environment and integrated health data systems have made it a global leader in population genomics and precision medicine research.
To dive further into Nordic life sciences companies, try Biotechgate for free today »